NO982281D0 - Sulfatkonjugater av ursodeoksycholinsyre og deres fordelaktige anvendelse - Google Patents
Sulfatkonjugater av ursodeoksycholinsyre og deres fordelaktige anvendelseInfo
- Publication number
- NO982281D0 NO982281D0 NO982281A NO982281A NO982281D0 NO 982281 D0 NO982281 D0 NO 982281D0 NO 982281 A NO982281 A NO 982281A NO 982281 A NO982281 A NO 982281A NO 982281 D0 NO982281 D0 NO 982281D0
- Authority
- NO
- Norway
- Prior art keywords
- udca
- sulfate
- tauro
- disulfate
- glyco
- Prior art date
Links
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 title abstract 10
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 title abstract 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title abstract 8
- 229960001661 ursodiol Drugs 0.000 title abstract 2
- 208000005623 Carcinogenesis Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 208000015634 Rectal Neoplasms Diseases 0.000 abstract 2
- 230000036952 cancer formation Effects 0.000 abstract 2
- 231100000504 carcinogenesis Toxicity 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 208000029742 colonic neoplasm Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 208000004804 Adenomatous Polyps Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 210000000941 bile Anatomy 0.000 abstract 1
- 230000010234 biliary secretion Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000003908 liver function Effects 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 206010038038 rectal cancer Diseases 0.000 abstract 1
- 210000000664 rectum Anatomy 0.000 abstract 1
- 201000001275 rectum cancer Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/560,992 US5763435A (en) | 1995-11-21 | 1995-11-21 | Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders |
| PCT/US1996/018487 WO1997018816A2 (en) | 1995-11-21 | 1996-11-19 | Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders and other applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO982281D0 true NO982281D0 (no) | 1998-05-19 |
| NO982281L NO982281L (no) | 1998-07-08 |
| NO317063B1 NO317063B1 (no) | 2004-08-02 |
Family
ID=24240215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19982281A NO317063B1 (no) | 1995-11-21 | 1998-05-19 | Anvendelse av UDCA (ursodeoksycholinsyre) for forebyggelse og behandling av leversykdom hos pattedyr |
| NO20042284A NO20042284D0 (no) | 1995-11-21 | 2004-06-02 | Sulfatkonjugater av ursodeoksycholinsyre og deres fordelaktige anvendelser ved inflammatoriske forstyrrelser og andre anvendelser |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20042284A NO20042284D0 (no) | 1995-11-21 | 2004-06-02 | Sulfatkonjugater av ursodeoksycholinsyre og deres fordelaktige anvendelser ved inflammatoriske forstyrrelser og andre anvendelser |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5763435A (no) |
| EP (1) | EP0871452B1 (no) |
| JP (3) | JP3836148B2 (no) |
| KR (1) | KR19990071521A (no) |
| CN (2) | CN100556408C (no) |
| AT (1) | ATE397450T1 (no) |
| AU (1) | AU709594B2 (no) |
| BR (1) | BR9611606A (no) |
| CA (1) | CA2238040C (no) |
| DE (1) | DE69637556D1 (no) |
| EA (1) | EA199800399A1 (no) |
| NO (2) | NO317063B1 (no) |
| NZ (1) | NZ323274A (no) |
| PL (1) | PL186393B1 (no) |
| WO (1) | WO1997018816A2 (no) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
| DE19645044A1 (de) * | 1996-10-31 | 1998-05-07 | Falk Pharma Gmbh | Verwendung von Ursodeoxycholsäure zur topischen Behandlung von Entzündungserkrankungen der Schleimhäute |
| AU758679B2 (en) * | 1998-07-24 | 2003-03-27 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| DE19906290A1 (de) * | 1999-02-15 | 2000-08-17 | Falk Pharma Gmbh | Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs |
| PT1158989E (pt) * | 1999-03-09 | 2007-10-01 | Hans-Dieter Volk | Terapia e utilização de agentes na terapia da caquexia e sintomas debilitantes devido a doenças para além da falha cardíaca congestiva |
| EP1284723A4 (en) * | 2000-04-19 | 2004-06-30 | Borody Thomas J | COMPILATIONS AND THERAPIES FOR HYPERLIPIDEMIA-ASSOCIATED DISEASES |
| US6596762B2 (en) | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
| US7053076B2 (en) | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| FR2829697B1 (fr) * | 2001-09-14 | 2004-03-19 | Mayoly Spindler Lab | Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin |
| ITTO20020102A1 (it) * | 2002-02-06 | 2003-08-06 | Abc Ist Biolog Chem Spa | Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili. |
| CN100421656C (zh) * | 2002-11-07 | 2008-10-01 | 明尼苏达大学评议会 | 乌索脱氧胆酸在制备治疗与出血相关的神经系统损伤的药物中的用途 |
| ITMI20030822A1 (it) * | 2003-04-18 | 2004-10-19 | Erregierre Spa | Processo per la preparazione dell'acido ursodesossicolico |
| EP2182856A2 (en) | 2007-08-08 | 2010-05-12 | Brian J. Cavanaugh | Method and apparatus for delivery of a ligating suture |
| EP2208497A1 (en) * | 2009-01-15 | 2010-07-21 | Charité-Universitätsmedizin Berlin (Charité) | Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient |
| IT1393095B1 (it) | 2009-02-19 | 2012-04-11 | Prodotti Chimici Alimentari | Processo per la sintesi del sale disodico dell'acido ursodesossicolico 3,7-disolfato. |
| WO2011053048A2 (ko) * | 2009-10-29 | 2011-05-05 | 연세대학교 산학협력단 | 신규 혈관누출 차단제 |
| US20130011413A1 (en) * | 2010-02-03 | 2013-01-10 | The University Of Tokyo | Method and Pharmaceutical Composition for Treatment of Intestinal Disease |
| US9724357B2 (en) | 2011-08-15 | 2017-08-08 | Massachusetts Eye & Ear Infirmary | Methods for preserving photoreceptor cell viability following retinal detachment |
| KR101953298B1 (ko) * | 2017-07-18 | 2019-02-28 | 의료법인 성광의료재단 | 우르소데옥시콜산을 함유하는 염증성 질환 또는 척수 손상 예방 또는 치료용 조성물 |
| US12186329B2 (en) | 2018-08-23 | 2025-01-07 | President And Fellows Of Harvard College | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes |
| WO2020117945A1 (en) | 2018-12-04 | 2020-06-11 | President And Fellows Of Harvard College | Synthetic derivatives of cholic acid 7-sulfate and uses thereof |
| CA3138346A1 (en) * | 2019-05-31 | 2020-12-03 | Metabolon, Inc. | Mass spectrometry assay methods for detection of metabolites |
| CA3148226A1 (en) | 2019-08-12 | 2021-02-18 | Massachusetts Institute Of Technology | Articles and methods for administration of therapeutic agents |
| WO2025130826A1 (en) * | 2023-12-18 | 2025-06-26 | Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences | Compositions and methods for treating cancer |
| CN117949648B (zh) * | 2024-03-26 | 2024-07-12 | 中国医学科学院北京协和医院 | 一种用于检测溃疡性结肠炎的标志物及用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1221734B (it) * | 1983-02-24 | 1990-07-12 | Schiena Michele Giuseppe Di | Ursodesossicolico solfato acido sale sodico |
| US5460812A (en) * | 1992-06-22 | 1995-10-24 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
-
1995
- 1995-11-21 US US08/560,992 patent/US5763435A/en not_active Expired - Lifetime
-
1996
- 1996-11-19 AT AT96940516T patent/ATE397450T1/de not_active IP Right Cessation
- 1996-11-19 KR KR1019980703793A patent/KR19990071521A/ko not_active Ceased
- 1996-11-19 EP EP96940516A patent/EP0871452B1/en not_active Expired - Lifetime
- 1996-11-19 CA CA002238040A patent/CA2238040C/en not_active Expired - Fee Related
- 1996-11-19 NZ NZ323274A patent/NZ323274A/en not_active IP Right Cessation
- 1996-11-19 EA EA199800399A patent/EA199800399A1/ru unknown
- 1996-11-19 DE DE69637556T patent/DE69637556D1/de not_active Expired - Lifetime
- 1996-11-19 CN CNB961997087A patent/CN100556408C/zh not_active Expired - Fee Related
- 1996-11-19 WO PCT/US1996/018487 patent/WO1997018816A2/en not_active Ceased
- 1996-11-19 AU AU77377/96A patent/AU709594B2/en not_active Ceased
- 1996-11-19 JP JP51982897A patent/JP3836148B2/ja not_active Expired - Fee Related
- 1996-11-19 PL PL96326931A patent/PL186393B1/pl not_active IP Right Cessation
- 1996-11-19 BR BR9611606-4A patent/BR9611606A/pt not_active Application Discontinuation
- 1996-11-19 CN CNA2009101273950A patent/CN101569632A/zh active Pending
-
1998
- 1998-02-24 US US09/028,036 patent/US6251884B1/en not_active Expired - Lifetime
- 1998-05-19 NO NO19982281A patent/NO317063B1/no not_active IP Right Cessation
-
2004
- 2004-06-02 NO NO20042284A patent/NO20042284D0/no not_active Application Discontinuation
-
2006
- 2006-01-11 JP JP2006003753A patent/JP4630195B2/ja not_active Expired - Fee Related
-
2010
- 2010-08-20 JP JP2010184945A patent/JP5277221B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| BR9611606A (pt) | 2000-10-24 |
| KR19990071521A (ko) | 1999-09-27 |
| WO1997018816A2 (en) | 1997-05-29 |
| AU7737796A (en) | 1997-06-11 |
| CN1211185A (zh) | 1999-03-17 |
| NZ323274A (en) | 2000-07-28 |
| NO20042284L (no) | 2004-06-02 |
| DE69637556D1 (de) | 2008-07-17 |
| AU709594B2 (en) | 1999-09-02 |
| CA2238040C (en) | 2004-07-13 |
| JP2006117698A (ja) | 2006-05-11 |
| JP2011006445A (ja) | 2011-01-13 |
| US5763435A (en) | 1998-06-09 |
| JP4630195B2 (ja) | 2011-02-09 |
| ATE397450T1 (de) | 2008-06-15 |
| MX9803988A (es) | 1998-10-31 |
| PL186393B1 (pl) | 2004-01-30 |
| NO982281L (no) | 1998-07-08 |
| CN101569632A (zh) | 2009-11-04 |
| US6251884B1 (en) | 2001-06-26 |
| JP5277221B2 (ja) | 2013-08-28 |
| PL326931A1 (en) | 1998-11-09 |
| WO1997018816A3 (en) | 1997-06-26 |
| CN100556408C (zh) | 2009-11-04 |
| NO317063B1 (no) | 2004-08-02 |
| NO20042284D0 (no) | 2004-06-02 |
| EP0871452B1 (en) | 2008-06-04 |
| EP0871452A2 (en) | 1998-10-21 |
| EA199800399A1 (ru) | 1998-12-24 |
| JP2000500764A (ja) | 2000-01-25 |
| CA2238040A1 (en) | 1997-05-29 |
| JP3836148B2 (ja) | 2006-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO982281D0 (no) | Sulfatkonjugater av ursodeoksycholinsyre og deres fordelaktige anvendelse | |
| Liu et al. | Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice | |
| Kojima et al. | Comparative effects of three chelating agents on distribution and excretion of cadmium in rats | |
| BRPI0206641B8 (pt) | uso de um inibidor da absorção de esteróis | |
| BR9909908A (pt) | Derivados de ácidos graxos de ácidos biliares e derivados de ácidos biliares | |
| TW362971B (en) | Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti | |
| ATE400264T1 (de) | Methoden zur behandlung von nierenversagen | |
| Seo et al. | Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model | |
| Chen et al. | Oleoylethanolamide stabilizes atherosclerotic plaque through regulating macrophage polarization via AMPK-PPARα pathway | |
| Kobylinska et al. | Biochemical indicators of hepatotoxicity in blood serum of rats under the effect of novel 4-thiazolidinone derivatives and doxorubicin and their complexes with polyethyleneglycol-containing nanoscale polymeric carrier | |
| Wollina et al. | Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix | |
| Van Molle et al. | Protection of zinc against tumor necrosis factor–induced lethal inflammation depends on heat shock protein 70 and allows safe antitumor therapy | |
| DK0514328T3 (da) | Chenodeoxycholsyre eller ursodeoxycholsyre til behandling af sygdomme i åndedrætsorganerne | |
| EP1545479A4 (en) | EZETIMIB COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHOLESTERIN-ASSOCIATED GOOD AND EVIL TUMORS | |
| KR940021064A (ko) | 프레그네인 유도체의 사용 방법 | |
| Yin et al. | Cisplatin causes erectile dysfunction by decreasing endothelial and smooth muscle content and inducing cavernosal nerve senescence in rats | |
| Gnanapragasam et al. | Insulin‐like growth factor II and androgen receptor expression in the prostate | |
| Schröder et al. | Xylocaine treatment in experimental pancreatitis in pigs | |
| Morris et al. | Regulation of plasma levels of aldosterone and its metabolites during the latent period of aldosterone | |
| CN112007038B (zh) | 血红素氧合酶-1诱导剂及其应用 | |
| Ishizaki et al. | Effect of sodium tauroursodeoxycholate (UR-906) on liver dysfunction in bile duct-ligated rats | |
| Xiao¹ et al. | Cisplatin causes erectile dysfunction by decreasing | |
| Palmer | The significance of bile salts metabolism | |
| SALTS | small intestine are (1) T-tube drainage of the common bile duct and (2) par-tial or complete interruption of ileal absorption, as in regional enteritis or | |
| Morris | Liver Resection: To Drain or not to Drain? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |